The overall goal of the Leukemia SPORE Developmental Research Program (LSDRP) is to recruit and support developmental research projects in leukemia for future peer-reviewed funding and/or future independent SPORE projects. The types of studies to be supported include projects in basic research, clinical research, epidemiologic studies, and cancer prevention and control research in leukemia. Projects supported under the LSRDP will expand the scope of translational research and increase the number of investigators committed to leukemia research. The LSDRP will work in tandem with the Career Development Program to assist in the development of junior investigators and in the recruitment and mentoring of minority investigators. To accomplish these goals, the following specific aims are proposed 1. To support developmental research projects in leukemia for future incorporation as full SPORE projects and for applications for other major peer-reviewed funding. New research projects will be solicited and funded using developmental funds. A total of $175,000 has been committed annually to this program (including $125,000 per year of matching funds from institutional sources). These funds will be used to support 3-5 developmental projects per year ranging from $30,000 to $60,000 throughout the life of the SPORE. 2. Foster collaborations between basic and clinical researchers. The LSDRP chairs will facilitate interaction between basic and clinical researchers through shared weekly meetings, the annual SPORE retreat, and small group meetings. 3. To provide mentoring to junior faculty. Ail investigators submitting developmental research projects will receive a written scientific and statistical review, and the LSDRP chairs will be available to discuss the projects in detail. Where appropriate, mentors will be identified to work with junior faculty.
The Developmental Research Program will recruit and support innovative early-stage research in leukemia.
|Duncavage, Eric J; Jacoby, Meagan A; Chang, Gue Su et al. (2018) Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med 379:1028-1041|
|Khoury, Hanna Jean; Langston, Amelia A; Kota, Vamsi K et al. (2018) Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant 53:826-831|
|Schroeder, Mark A; Choi, Jaebok; Staser, Karl et al. (2018) The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant 24:1125-1134|
|Perry, Justin S A; Russler-Germain, Emilie V; Zhou, You W et al. (2018) CD36 Mediates Cell-Surface Antigens to Promote Thymic Development of the Regulatory T Cell Receptor Repertoire and Allo-tolerance. Immunity 48:923-936.e4|
|Wong, Terrence N; Miller, Christopher A; Jotte, Matthew R M et al. (2018) Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun 9:455|
|Christopher, Matthew J; Petti, Allegra A; Rettig, Michael P et al. (2018) Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med 379:2330-2341|
|Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521|
|Jacoby, Meagan A; Duncavage, Eric J; Chang, Gue Su et al. (2018) Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight 3:|
|Monlish, Darlene A; Bhatt, Sima T; Duncavage, Eric J et al. (2018) Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS. Blood 131:1032-1035|
|Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494|
Showing the most recent 10 out of 64 publications